87694-52-8

Basic information

• Product Name: BOC-L-LEUCINE N,O-DIMETHYLHYDROXAMIDE
• Synonyms: BOC-VAL-NME(OME);BOC-VAL-N(OCH3)CH3;BOC-L-VALINE N-METHOXY-N-METHYL AMIDE;BOC-L-VALINE N,O-DIMETHYLHYDROXAMIDE;BOC-L-LEUCINE N,O-DIMETHYLHYDROXAMIDE;BOC-LEU-NME(OME);BOC-LEU-N(OME)ME;N-ALPHA-T-BOC-L-VALINE N-METHOXY-N-METHYL AMIDE
• CAS NO: 87694-52-8
• Molecular Formula: C₁₂H₂₄N₂O₄
• Molecular Weight: 260.33
• Product Categories: Amino Acids;Amino Acid Derivatives;Peptide Synthesis;Valine
• Mol File: 87694-52-8.mol
• Article Data: 46

Chemical Properties

• Boiling Point: 235 °C(lit.)
• Flash Point: >230 °F
• Appearance: White to pale yellow/Low Melting Solid or Liquid
• Density: 1.46 g/mL at 25 °C(lit.)
• Refractive Index: n20/D 1.454(lit.)
• Storage Temp.: Store at 0-5°C
• PKA: 11.11±0.46(Predicted)
• CAS DataBase Reference: BOC-L-LEUCINE N,O-DIMETHYLHYDROXAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-L-LEUCINE N,O-DIMETHYLHYDROXAMIDE(87694-52-8)
• EPA Substance Registry System: BOC-L-LEUCINE N,O-DIMETHYLHYDROXAMIDE(87694-52-8)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 87694-52-8(Hazardous Substances Data)

Usage

Chemical Properties

White to off-white crystalline powder

Uses

Reduced by LiAlH4 to give the corresponding Boc amino acid aldehyde.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 72-18-4 L-valine 
• 54430-66-9 [(1S)-1-(imidazole-1-carbonyl)-2-methylpropyl]-carbamic acid tert-butyl ester 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 13734-41-3 t-Boc-L-valine 
• 133010-02-3 1,1-dimethylethyl S-N-(1-fluorocarbonyl-2-methylpropyl)carbamate 
• 1117-97-1 N,0-dimethylhydroxylamine 

Downstream Products

• 143327-78-0 tert-butyl [(1S)-1-isopropylprop-2-yn-1-yl]carbamate 
• 1025959-11-8 [1-(4-fluoro-benzoyl)-2-methyl-propyl]-carbamic acid tert-butyl ester 
• 295800-05-4 (S)-tert-butyl (3-methyl-1-oxo-1-phenylbutan-2-yl)carbamate 
• 79069-51-5 (S)-N-tert-butoxycarbonylvalinal 
• 145037-78-1 (3S)-3-(tert-butyloxycarbonylamino)-4-methyl-1-phenylpentan-2-one 
• 1136153-43-9 tert-butyl [(1S,2S)-1-(hydroxy(phenyl)methyl)-2-methyl-propyl]-carbamate 

Relevant articles and documents

Design, Synthesis, and Biological Activity of Isosyringolin A

Isosyringolin A, which is an isomer of the proteasome-inhibiting natural product syringolin A, was designed and synthesized to develop analogues that are step economical and synthetically accessible in a practical manner. It was revealed that isosyringolin A exhibited proteasome-inhibitory activity comparable to that of syringolin A and that its derivatization leads to great enhancement in its proteasome inhibitory activity as well as its cytotoxicity against human myeloma cells.

Convenient Synthesis of Alternatively Bridged Tryptophan Ketopiperazines and Their Activities against Trypanosomatid Parasites

There is an urgent need for the development of new treatments against trypanosomatid parasites; the causative agents of some of the most debilitating diseases in the developing world. This work targets an interesting 6-5-6-6 fused carboline scaffold, accessing a range of substituted derivatives through stereospecific intramolecular Pictet–Spengler condensation. Modification of the cyclisation conditions allowed retention of the carbamate protecting group and gave insight into the reaction mechanism. Compounds’ bioactivities were measured against T. brucei, T. cruzi, L. major and HeLa cells. We have identified promising pan-trypanocidal lead compounds based on the core scaffold, and highlight key SAR trends which will be useful for the future development of these compounds as potent trypanocidal agents.

PYRROLIDINE DERIVATIVE

The present invention aims to provide a novel compound which has CGRP receptor antagonist activity and which is useful for the treatment of various diseases mediated by CGRP receptors. That is, the present invention relates to the pyrrolidine derivatives represented by the following formula (I) or a pharmaceutically acceptable salt thereof. In the formulae, W is ring, X is a carbon atom or the like, Y1 to Y4 are carbon atoms or the like, and R1 to R7 is alkyl or the like. The compounds of the present invention or a pharmaceutically acceptable salt thereof have an excellent CGRP receptor antagonist activity, and thus are useful as agents for the treatment of various diseases mediated by CGRP receptors.